Table 4 Secondary outcomes expressed as weighted mean differences between intervention and control groups
WMD | 95% CI | p | |
|---|---|---|---|
Diabetes guideline | |||
HbA1c < 7% | −3.05 | −9.16 to 3.07 | 0.320 |
Annual general laboratory testing | 3.83 | −30.74 to 38.41 | 0.824 |
Annual coronary risk assessment | 28.16 | 7.22 to 49.08 | 0.010 |
Annual foot examination | 13.08 | −5.30 to 31.45 | 0.158 |
Blood pressure < 140/80 mmHg | −2.52 | −12.10 to 7.06 | 0.598 |
Metformin/All new antidiabetic monotherapy | 17.83 | −3.22 to 38.88 | 0.095 |
Hypertension guideline | |||
Blood pressure < 140/90 mmHg | 3.76 | −4.14 to 11.66 | 0.342 |
Annual coronary risk assessment | 27.55 | 7.38 to 47.71 | 0.009 |
Diuretics/All new antihypertensive monotherapy | 20.58 | 6.44 a 34.73 | 0.005 |
Beta blockers/All new antihypertensive monotherapy | −8.24 | −21.77 to 5.29 | 0.226 |
ARB-II/All new antihypertensive monotherapy | 11.32 | −10.16 to 32.81 | 0.293 |
Dyslipidemia guideline | |||
New statin treatments with previous coronary risk assessment | 23.09 | 7.26 to 38.92 | 0.005 |
New statin treatments in low-risk women | −3.08 | −5.20 to −0.94 | 0.006 |
Patients with coronary heart disease receiving statin treatment | 13.47 | −14.36 to 41.30 | 0.334 |